Current Prospective in the Management of Depression Using Off-Label Drugs and Advanced Drugs

The paper reviews the management of depression using off-label and advanced drugs, emphasizing the importance of assessing depression severity based on functional impairment. It highlights the need to differentiate between major depressive disorder (MDD) and bipolar disorder to avoid misdiagnosis. The role of primary care physicians in suicide prevention and the potential of electroencephalography (EEG) in identifying depression are discussed. The paper notes the recent FDA approval of esketamine nasal spray for treatment-resistant depression and brexanolone IV injection for postpartum depression. The conclusion underscores the increasing use of antidepressants and the importance of treating depression as a chronic condition, with new medications offering promising advancements in therapy.